Genetic advances of type 2 diabetes in Chinese populations

Journal of Diabetes

Volumn 4, Issue 3, 2012, Pages 213-220

  Yu, Weihui ^a   Hu, Cheng ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Chinese populations; Genetic studies; Pharmacogenomics; Risk prediction; Type 2 diabetes

Indexed keywords

INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; POTASSIUM CHANNEL KCNQ1; REPAGLINIDE; ROSIGLITAZONE;

BODY MASS; CHINESE; DISEASE PREDISPOSITION; DRUG EFFICACY; ETHNICITY; GENE LOCUS; GENE REPLICATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GLUCOSE METABOLISM; HERITABILITY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPOGLYCEMIC AGENTS; PHARMACOGENETICS;

EID: 84865339867     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00225.x     Document Type: Review

References (89)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-53.
2. Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-101.
3. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet. 2005; 365: 1333-46.
4. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010; 375: 408-18.
5. O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 diabetes: The end of the beginning? Science. 2005; 307: 370-3.
6. Lee JW, Brancati FL, Yeh HC. Trends in the prevalence of type 2 diabetes in Asians versus Whites: Results from the United States National Health Interview Survey, 1997-2008. Diabetes Care. 2011; 34: 353-7.
7. Yoon KH, Lee JH, Kim JW et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368: 1681-8.
8. Chan JC, Malik V, Jia W et al. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301: 2129-40.
9. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: Results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr. 2007; 86: 353-9.
10. Torrens JI, Skurnick J, Davidow AL et al. Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: The Study of Women's Health Across the Nation (SWAN). Diabetes Care. 2004; 27: 354-61.
11. Hu C, Zhang R, Wang C et al. PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a Chinese population. PLoS ONE. 2009; 4: e7643.
12. Wang C, Hu C, Zhang R et al. Common variants of hepatocyte nuclear factor 1beta are associated with type 2 diabetes in a Chinese population. Diabetes. 2009; 58: 1023-7.
13. Xiang J, Li XY, Xu M et al. Zinc transporter-8 gene (SLC30A8) is associated with type 2 diabetes in Chinese. J Clin Endocrinol Metab. 2008; 93: 4107-12.
14. Xu M, Bi Y, Xu Y et al. Combined effects of 19 common variations on type 2 diabetes in Chinese: Results from two community-based studies. PLoS ONE. 2010; 5: e14022.
15. Wu Y, Li H, Loos RJ et al. Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes. 2008; 57: 2834-42.
16. Liu Y, Liu Z, Song Y et al. Meta-analysis added power to identify variants in FTO associated with type 2 diabetes and obesity in the Asian population. Obesity. 2010; 18: 1619-24.
17. Liu Y, Yu L, Zhang D et al. Positive association between variations in CDKAL1 and type 2 diabetes in Han Chinese individuals. Diabetologia. 2008; 51: 2134-7.
18. Wen J, Ronn T, Olsson A et al. Investigation of type 2 diabetes risk alleles support CDKN2A/B, CDKAL1, and TCF7L2 as susceptibility genes in a Han Chinese cohort. PLoS ONE. 2010; 5: e9153.
19. Ronn T, Wen J, Yang Z et al. A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals. Diabetologia. 2009; 52: 830-3.
20. Ng MC, Tam CH, Lam VK, So WY, Ma RC, Chan JC. Replication and identification of novel variants at TCF7L2 associated with type 2 diabetes in Hong Kong Chinese. J Clin Endocrinol Metab. 2007; 92: 3733-7.
21. Ng MC, Park KS, Oh B et al. Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6, 719 Asians. Diabetes. 2008; 57: 2226-33.
22. Chang YC, Chang TJ, Jiang YD et al. Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes. 2007; 56: 2631-7.
23. Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006; 38: 320-3.
24. Gaulton KJ, Nammo T, Pasquali L et al. A map of open chromatin in human pancreatic islets. Nat Genet. 2010; 42: 255-9.
25. Hu C, Zhang R, Wang C et al. Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. PLoS ONE. 2010; 5: e15542.
26. Prokopenko I, Langenberg C, Florez JC et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009; 41: 77-81.
27. Lyssenko V, Nagorny CL, Erdos MR et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009; 41: 82-8.
28. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009; 41: 89-94.
29. Bouatia-Naji N, Rocheleau G, Van Lommel L et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science. 2008; 320: 1085-8.
30. Chen WM, Erdos MR, Jackson AU et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest. 2008; 118: 2620-8.
31. Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010; 42: 105-16.
32. Saxena R, Hivert MF, Langenberg C et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010; 42: 142-8.
33. Strawbridge RJ, Dupuis J, Prokopenko I et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011; 60: 2624-34.
34. Hu C, Zhang R, Wang C et al. A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia. 2009; 52: 451-6.
35. Hu C, Zhang R, Wang C et al. Effects of GCK, GCKR, G6PC2 and MTNR1B variants on glucose metabolism and insulin secretion. PLoS ONE. 2010; 5: e11761.
36. Liu C, Li H, Qi L et al. Variants in GLIS3 and CRY2 are associated with type 2 diabetes and impaired fasting glucose in Chinese Hans. PLoS ONE. 2011; 6: e21464.
37. Qi Q, Wu Y, Li H et al. Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population. Diabetologia. 2009; 52: 834-43.
38. Tam CH, Ho JS, Wang Y et al. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects. PLoS ONE. 2010; 5: e11428.
39. Liu PH, Chang YC, Jiang YD et al. Genetic variants of TCF7L2 are associated with insulin resistance and related metabolic phenotypes in Taiwanese adolescents and Caucasian young adults. J Clin Endocrinol Metab. 2009; 94: 3575-82.
40. Bonnefond A, Froguel P, Vaxillaire M. The emerging genetics of type 2 diabetes. Trends Mol Med. 2010; 16: 407-16.
41. Ingelsson E, Langenberg C, Hivert MF et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes. 2010; 59: 1266-75.
42. Hutton JC, O'Brien RM. Glucose-6-phosphatase catalytic subunit gene family. J Biol Chem. 2009; 284: 29241-5.
43. Unoki H, Takahashi A, Kawaguchi T et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet. 2008; 40: 1098-102.
44. Yasuda K, Miyake K, Horikawa Y et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet. 2008; 40: 1092-7.
45. Yamauchi T, Hara K, Maeda S et al. A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet. 2010; 42: 864-8.
46. Hu C, Wang C, Zhang R et al. Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia. 2009; 52: 1322-5.
47. Liu Y, Zhou DZ, Zhang D et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes in the population of mainland China. Diabetologia. 2009; 52: 1315-21.
48. Qi Q, Li H, Loos RJ et al. Common variants in KCNQ1 are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Hum Mol Genet. 2009; 18: 3508-15.
49. Cui B, Zhu X, Xu M et al. A genome-wide association study confirms previously reported loci for type 2 diabetes in Han Chinese. PLoS ONE. 2011; 6: e22353.
50. Tsai FJ, Yang CF, Chen CC et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet. 2010; 6: e1000847.
51. Shu XO, Long J, Cai Q et al. Identification of new genetic risk variants for type 2 diabetes. PLoS Genet. 2010; 6: e1001127.
52. Voight BF, Scott LJ, Steinthorsdottir V et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010; 42: 579-89.
53. Cho YS, Chen CH, Hu C et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet. 2011; 44: 67-72.
54. Xiang K, Wang Y, Zheng T et al. Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: Significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes. 2004; 53: 228-34.
55. Elbein SC, Hoffman MD, Teng K, Leppert MF, Hasstedt SJ. A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes. 1999; 48: 1175-82.
56. Hanson RL, Ehm MG, Pettitt DJ et al. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet. 1998; 63: 1130-8.
57. Hsueh WC, St Jean PL, Mitchell BD et al. Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: Evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromosome 1q21-q24. Diabetes. 2003; 52: 550-7.
58. Langefeld CD, Wagenknecht LE, Rotter JI et al. Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: The Insulin Resistance Atherosclerosis Study Family Study. Diabetes. 2004; 53: 1170-4.
59. Ng MC, So WY, Cox NJ et al. Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes. 2004; 53: 1609-13.
60. Vionnet N, Hani EH, Dupont S et al. Genomewide search for type 2 diabetes-susceptibility genes in French Whites: Evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet. 2000; 67: 1470-80.
61. Wiltshire S, Hattersley AT, Hitman GA et al. A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): Analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet. 2001; 69: 553-69.
62. Prokopenko I, Zeggini E, Hanson RL et al. Linkage disequilibrium mapping of the replicated type 2 diabetes linkage signal on chromosome 1q. Diabetes. 2009; 58: 1704-9.
63. Hu C, Wang C, Zhang R et al. Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population. Diabetologia. 2010; 53: 290-8.
64. Talmud PJ, Hingorani AD, Cooper JA et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ. 2010; 340: b4838.
65. Cornelis MC, Qi L, Zhang C et al. Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. Ann Intern Med. 2009; 150: 541-50.
66. Sparso T, Grarup N, Andreasen C et al. Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia. 2009; 52: 1308-14.
67. van Hoek M, Dehghan A, Witteman JC et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: A population-based study. Diabetes. 2008; 57: 3122-8.
68. Qi Q, Li H, Wu Y et al. Combined effects of 17 common genetic variants on type 2 diabetes risk in a Han Chinese population. Diabetologia. 2010; 53: 2163-6.
69. Meigs JB, Shrader P, Sullivan LM et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008; 359: 2208-19.
70. Lyssenko V, Jonsson A, Almgren P et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008; 359: 2220-32.
71. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006; 57: 119-37.
72. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011; 364: 1144-53.
73. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011; 43: 117-20.
74. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003; 74: 380-7.
75. Niemi M, Backman JT, Kajosaari LI et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005; 77: 468-78.
76. Yu M, Xu XJ, Yin JY et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther. 2010; 87: 330-5.
77. Ruzilawati AB, Gan SH. CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics. Pharmacology. 2010; 85: 357-64.
78. Huang Q, Yin JY, Dai XP et al. IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population. Acta Pharmacol Sin. 2010; 31: 709-17.
79. Huang Q, Yin JY, Dai XP et al. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol. 2010; 66: 1207-15.
80. Sheng FF, Dai XP, Qu J et al. NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2011; 38: 550-4.
81. Wang S, Se YM, Liu ZQ et al. Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes. Pharmazie. 2012; 67: 74-9.
82. Xiang Q, Cui YM, Zhao X, Yan L, Zhou Y. The influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers. Pharmacology. 2012; 89: 105-10.
83. Gong ZC, Huang Q, Dai XP et al. NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patient with type 2 diabetes. Br J Clin Pharmacol. 2012; Epub 1 February 2012; doi: 10.1111/j.1365-2125.2012.04202.x.
84. He YY, Zhang R, Shao XY et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol Sin. 2008; 29: 983-9.
85. Qin W, Zhang R, Hu C et al. A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. Acta Pharmacol Sin. 2010; 31: 450-4.
86. Yu W, Hu C, Zhang R et al. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin Pharmacol Ther. 2011; 89: 437-42.
87. Dai XP, Huang Q, Yin JY et al. KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese Type 2 diabetic patients. Clin Exp Pharmacol Physiol. 2012; 39: 462-8.
88. Wang J, Bao YQ, Hu C et al. Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. Acta Pharmacol Sin. 2008; 29: 252-8.
89. Jiang F, Li Q, Hu C et al. Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China. Biomed Environ Sci. 2012; 25: 23-9.